Drug Trial Radar · NCT05335122
A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)
Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
83
Actual
Start
Mar 16, 2022
Primary completion
Jan 24, 2024
Study completion Jan 24, 2025
Sponsor
- Lead sponsor
- Ocular Therapeutix, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 19, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess efficacy, and safety of a single sustained release dose of the OTX-TIC drug product (2 travoprost dose strengths) in subjects with Open Angle Glaucoma (OAG) or Ocular Hypertension (OHT)
Conditions
- Open Angle Glaucoma
- Ocular Hypertension
Interventions
OTX-TIC low dose Travoprost Intracameral ImplantDrug
OTX-TIC implant is injected into the anterior chamber of the eye.
OTX-TIC high dose Travoprost Intracameral ImplantDrug
OTX-TIC implant is injected into the anterior chamber of the eye.
Durysta, Bimatoprost Intracameral Implant 10 µgDrug
Durysta is injected into the anterior chamber of the eye.
Primary outcomes
What the sponsor says the trial is designed to measure.
- IOP Changes From Baseline in the Study EyeTime frame: Baseline (8AM, 10 AM, 4 PM) to Week 2 (8 AM, 10 AM, 4 PM) Baseline (8AM, 10 AM, 4 PM) to Week 6 (8 AM, 10 AM, 4 PM) Baseline (8AM, 10 AM, 4 PM) to Week 12 (8 AM, 10 AM, 4 PM)
Locations
30 sites in 1 country. Site status is shown where the registry gives one.
Ocular Therapeutix, Inc.
Dothan, Alabama
Ocular Therapeutix, Inc.
Huntington Beach, California
Ocular Therapeutix, Inc.
Irvine, California
Ocular Therapeutix, Inc.
Los Angeles, California
Ocular Therapeutix, Inc.
Pasadena, California
Ocular Therapeutix, Inc.
Petaluma, California
Ocular Therapeutix, Inc.
Redlands, California
Ocular Therapeutix, Inc.
Torrance, California
Ocular Therapeutix, Inc.
Clearwater, Florida
Ocular Therapeutiux, Inc.
Delray Beach, Florida
Ocular Therapeutix, Inc.
Fort Myers, Florida
Ocular Therapeutix, Inc.
Roswell, Georgia
Ocular Therapeutix, Inc.
Rock Island, Illinois
Ocular Therapeutix Inc
Carmel, Indiana
Ocular Therapeutix, Inc.
Saint Joseph, Michigan
Ocular Therapeutix, Inc.
Saint Joseph, Missouri
Ocular Therapeutix Inc.
St Louis, Missouri
Ocular Therapeutix, Inc.
Dover, New Jersey
Ocular Therapeutix, Inc.
Troy, New York
Ocular Therapeutix, Inc.
Durham, North Carolina
Ocular Therapeutiux, Inc.
Fargo, North Dakota
Ocular Therapeutix, Inc.
Cleveland, Ohio
Ocular Therapeutix Inc
Oklahoma City, Oklahoma
Ocular Therapeutix, Inc.
Cranberry Township, Pennsylvania
Ocular Therapeutix, Inc.
Philadelphia, Pennsylvania
Ocular Therapeutix, Inc.
Austin, Texas
Ocular Therapeutix, Inc.
Dallas, Texas
Ocular Therapeutix, Inc.
El Paso, Texas
Ocular Therapeutix, Inc.
Houston, Texas
Ocular Therapeutix, Inc.
Kenosha, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.